Everest Medicines Limited 1952.HK Stock
Everest Medicines Limited Price Chart
Everest Medicines Limited 1952.HK Financial and Trading Overview
Everest Medicines Limited stock price | 22.1 HKD |
Previous Close | 17.28 HKD |
Open | 16.84 HKD |
Bid | 16.1 HKD x N/A |
Ask | 16.14 HKD x N/A |
Day's Range | 15.7 - 17.82 HKD |
52 Week Range | 5.98 - 30 HKD |
Volume | 15.93M HKD |
Avg. Volume | 3.52M HKD |
Market Cap | 4.92B HKD |
Beta (5Y Monthly) | 2.465517 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.91 HKD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 22.95 HKD |
1952.HK Valuation Measures
Enterprise Value | 4.16B HKD |
Trailing P/E | N/A |
Forward P/E | -5.9851303 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 384.45044 |
Price/Book (mrq) | 0.8697532 |
Enterprise Value/Revenue | 325.328 |
Enterprise Value/EBITDA | -2.992 |
Trading Information
Everest Medicines Limited Stock Price History
Beta (5Y Monthly) | 2.465517 |
52-Week Change | -11.019% |
S&P500 52-Week Change | 20.43% |
52 Week High | 30 HKD |
52 Week Low | 5.98 HKD |
50-Day Moving Average | 13.46 HKD |
200-Day Moving Average | 13.91 HKD |
1952.HK Share Statistics
Avg. Volume (3 month) | 3.52M HKD |
Avg. Daily Volume (10-Days) | 4.57M HKD |
Shares Outstanding | 305.46M |
Float | 155.52M |
Short Ratio | N/A |
% Held by Insiders | 0.088% |
% Held by Institutions | 62.37% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | December 31, 2022 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -10981.12% |
Gross Margin | 63.68% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -13.24% |
Return on Equity (ttm) | -4.28% |
Income Statement
Revenue (ttm) | 12.79M HKD |
Revenue Per Share (ttm) | 0.04 HKD |
Quarterly Revenue Growth (yoy) | 21655.60% |
Gross Profit (ttm) | N/A |
EBITDA | -1390893952 HKD |
Net Income Avi to Common (ttm) | -247283008 HKD |
Diluted EPS (ttm) | -1.46 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 1.65B HKD |
Total Cash Per Share (mrq) | 5.41 HKD |
Total Debt (mrq) | 534.64M HKD |
Total Debt/Equity (mrq) | 9.46 HKD |
Current Ratio (mrq) | 3.924 |
Book Value Per Share (mrq) | 18.511 |
Cash Flow Statement
Operating Cash Flow (ttm) | -1155761024 HKD |
Levered Free Cash Flow (ttm) | -2031207936 HKD |
Profile of Everest Medicines Limited
Country | Hong Kong |
State | N/A |
City | Shanghai |
Address | CITIC Pacific Plaza |
ZIP | 200041 |
Phone | N/A |
Website | https://www.everestmedicines.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 365 |
Everest Medicines Limited, a biopharmaceutical company, engages in discovery, licensing, clinical development, and commercialization of therapies and vaccines to address critical unmet medical needs in Greater China and other Asia Pacific markets. Its pipeline products include 9 clinical-stage drug candidates for the treatment of oncology, immunology, cardio-renal, and infectious diseases. The company offers Nefecon, an oral formulation of budesonide for the treatment of primary immunoglobulin nephropathy (IgAN); EVER001, a covalent reversible Bruton's tyrosine kinase (BTK) inhibitor which is in the phase 1b/2 clinical trial for the treatment of renal diseases; PTX-COVID19-B, a lipid nanoparticle-formulated mRNA COVID-19 vaccine; EVER-COVID19-M1, an Omicron-targeting bivalent COVID-19 booster vaccine; and mRNA rabies vaccine. Further, its pipeline includes Eravacycline, a fully synthetic fluorocycline intravenous antibiotic for the treatment of infections caused by susceptible gram-positive, gram-negative, and anaerobic pathogens; Taniborbactam, a beta-lactamase inhibitor (BLI) which is in phase 3 clinical trial for the treatment of patients with serious bacterial infections; EVER206, a polymyxin derivative designed to reduce toxicity and nephrotoxicity which is in phase 1 of clinical trial; and FGF401 is an ATP-competitive, reversible-covalent inhibitor of FGFR4 which is in phase 1/2 of clinical trial. Everest Medicines Limited was incorporated in 2017 and is headquartered in Shanghai, China.
Q&A For Everest Medicines Limited Stock
What is a current 1952.HK stock price?
Everest Medicines Limited 1952.HK stock price today per share is 22.1 HKD.
How to purchase Everest Medicines Limited stock?
You can buy 1952.HK shares on the HKSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Everest Medicines Limited?
The stock symbol or ticker of Everest Medicines Limited is 1952.HK.
Which industry does the Everest Medicines Limited company belong to?
The Everest Medicines Limited industry is Biotechnology.
How many shares does Everest Medicines Limited have in circulation?
The max supply of Everest Medicines Limited shares is 319.36M.
What is Everest Medicines Limited Price to Earnings Ratio (PE Ratio)?
Everest Medicines Limited PE Ratio is now.
What was Everest Medicines Limited earnings per share over the trailing 12 months (TTM)?
Everest Medicines Limited EPS is -2.91 HKD over the trailing 12 months.
Which sector does the Everest Medicines Limited company belong to?
The Everest Medicines Limited sector is Healthcare.
Everest Medicines Limited 1952.HK included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
Nasdaq EM Plus Korea Small Cap NQEMKRSCGBP | 1476.35 GBP 1888.16 USD |
<0.01
|
— — | 1476.35 GBP 1888.16 USD | 1476.35 GBP 1888.16 USD | — - | — — |
- {{ link.label }} {{link}}